Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01106508 : A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Confirmed diagnosis of advanced solid tumor, recurrent or refractory medulloblastoma
or locally advanced or metastatic basal cell carcinoma)

- Protocol defined laboratory parameters

- Performance status ? 2

- Patients must have fully recovered from the prior effects of major surgery and from
any acute toxicities of prior chemotherapy/radiotherapy

Exclusion Criteria:

- History of central nervous system tumors of symptomatic brain metastases (excludes
medulloblastoma patients)

- Impairment of gastrointestinal function or unresolved nausea, vomiting or diarrhea

- Impairment of cardiac function or significant cardiac disease

- Pregnant or lactating women

- Other protocol-defined inclusion/exclusion criteria may apply
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557